eart failure may be defined as the inability of the heart to meet the demands of the tissues, resulting in symptoms of fatigue or dyspnea on exertion progressing to dyspnea at rest. Patients with nonischemic dilated cardiomyopathy (NIDCM) constitute the largest group of myopathic disorders that are responsible for systolic heart failure. In most multicenter, randomized heart-failure trials, approximately one-third of the enrolled patients have NIDCM. The term NIDCM refers to a spectrum of heterogeneous myocardial disorders that are characterized by ventricular dilation and depressed myocardial contractility in the absence of abnormal loading conditions (such as hypertension or valvular disease) or ischemic heart disease.
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Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) and -blockers are the mainstay of treatment in patients with heart failure, irrespective of the etiology and severity of heart failure. ACEI/ARBs and -blockers have been shown to reverse left ventricular (LV) remodeling and improve dyspnea and exercise tolerance, reduce hospitalization rates, and reduce cardiovascular mortality.
The prognosis of dilated cardiomyopathy (DCM) has been poor in the past, 1 and -blockers have been widely used as treatment. Azuma et al reported that in Japan the calculated survival rate at 5 years was 90.0% in patients diagnosed with DCM after 1990 in contrast to 62.3% in patients diagnosed before 1989. 3 However, there are still some cases that remain difficult to treat despite the use of ACEI/ARBs and -blockers, and for these biventricular pacing or surgical interventions, such as heart transplantation or the Batista procedure, has been performed. Therefore, risk prediction in patients with NIDCM is crucial for selection of the best treatment strategy, but there were few reports restricted to cases of NIDCM for examining the predictive factors of heart failure.
The purpose of this study was to evaluate various factors that might predict an adverse outcome in patients with NIDCM who were treated with ACEI/ARBs and/orblockers.
Methods

Patient Selection
We identified 78 consecutive patients with NIDCM between 1997 and 2002. NIDCM was diagnosed by echocardiography, coronary angiography, and endomyocardial biopsy, according to the criteria proposed by the WHO/ISFC task force. NIDCM was defined as LV ejection fraction (LVEF) <0.40, a LV end-diastolic diameter (LVEDD) >55 mm on echocardiography, and the absence of significant coronary artery stenosis on angiography. Exclusion criteria included severe lung disease, liver or renal failure, a permanent pacemaker, or previous history of heart failure.
Follow-up
The follow-up period of all patients started at the time of diagnosis of NIDCM. After diagnosis, they were treated with optimal medical therapy including ACEI/ARB and/or -blockers: 69 patients were treated with ACEI or ARB (temocapril: 4 cases, mean dose =1.5 mg; trandolapril: 2 cases, 4 mg; losartan: 11 cases, 50 mg; enalapril: 46 cases, 4.6 mg; candesartan: 3 cases, 8 mg; valsartan: 3 cases, 80 mg); the remaining 9 patients received -blockers and all patients received at least one of an ACEI, ARB orblocker. Beta-blockers included carvediol and celiprolol (carvediol: 46 cases, mean dose =10.2 mg; celiprolol: 1 case, 100 mg). No patient discontinued medication during follow-up. The clinical endpoint was heart failure progression defined either as death or hospitalization because of deterioration of heart failure.
Electrocardiographic Evaluation
Electrocardiographic studies were performed at the first diagnosis of NIDCM and computed values of QRS duration were recorded. QRS duration was determined as the calculated mean value of the QRS duration in all 12-leads. We did not exclude cases with bundle bunch block.
Echocardiographic Evaluation
Echocardiography was performed at the first diagnosis of NIDCM. LV dimensions were measured through the standard left parasternal window at end diastole (LVEDD) at the time of the R wave on electrocardiogram (ECG) and at end systole just below the level of mitral leaflets. LVEF was calculated by the Teichholz formula. Left atrial diameter (LAd) was obtained from the parasternal long-axis view. Color flow Doppler imaging was used to determine the presence and severity of mitral regurgitation (MR), which was graded according to the extent and width of the regurgitant jet: none (0), mild (1), moderate (2), moderate to severe (3), or severe (4) .
In 61 patients, follow-up echocardiographic studies were performed after a mean of 19 months. We defined the percentage change in LVEDD as: (LVEDD measured during follow-up after optimal medical therapy -LVEDD measured at the first diagnosis of NIDCM)/LVEDD measured at the first diagnosis of NIDCM.
Hemodynamic Evaluation
A Swan-Ganz thermodilution catheter was introduced through the femoral vein and positioned in the pulmonary artery for determination of cardiac output.
Statistical Analysis
All continuous values are expressed as the mean ± SD. Univariate and multivariate stepwise logistic regression analyses were used to identify the significant predictors of negative events (cardiac death or hospitalization because of deterioration of heart failure). The following variables were entered into the model: age, sex, drug profile (ie, -blocker or ACEI inhibitor/ARB) echocardiographic data (LVEF, LVEDD, LAd and the severity of MR), Swan-Ganz hemodynamic data (cardiac index and pulmonary capillary wedge pressure (PCWP)), presence of atrial fibrillation (AF), New York Heart Association (NYHA) class and QRS duration on ECG. A p-value <0.05 was considered statistically significant and all measurements that were found to be independent predictors of negative events in the univariate analysis were included in the multivariate Cox proportional hazard stepwise analysis. We divided the patient population into 2 groups according to the variables that were found to be independent predictors of negative events in the multivariate analysis. Continuous variables were compared between the groups by analysis of variance. Tabular data were compared using chi-square or Fisher's exact test. The Kaplan-Meier method was used to calculate survival curves and a log-rank test was used to compare survival curves among the different patient groups. 
Results
Patient Characteristics
The clinical characteristics of the 78 patients are shown in Table 1 . The study population comprised 66 men and 12 women, with a mean age of 57±12 years. The distribution of patients based on their NYHA functional class was as follows: class I (n=31), class II (n=19), class III (n=15), class IV (n=13). During 36.6±23.8 months (range, 4-101 months) of follow-up, cardiac death and hospitalization because of deterioration of congestive heart failure occurred in 23 patients (29.5%) (sudden death, 2; hospitalization, 21).
Univariate and Multivariate Predictors of Outcome
The results of the univariate and multivariate Cox proportional hazards regression analyses of cardiac death and hospitalization because of deterioration of heart failure are presented in Tables 2 and 3 . In the univariate analysis, QRS duration, severity of MR, LVEDD, LVEF and PCWP predicted cardiac events. In the multivariate Cox analysis, significant predictors of cardiac events were LVEF (chi-square, 5.74; p=0.0166), severity of MR (chi-square, 12.31; p= 0.0004) and QRS duration (chi-square, 11.20; p=0.0008).
QRS Duration We divided the patient population into 2 Kaplan-Meier event-free curves for nonischemic dilated cardiomyopathy patients stratified into 2 groups according to QRS duration. Cardiac death and hospitalization due to the deterioration of heart failure were defined as negative events.
groups on the basis of a QRS duration of 120 ms (Table 4) . At the time of the diagnosis of NIDCM, 52 patients (66.6%) had a QRS duration <120 ms, and 26 patients (33.3%) had a QRS duration ≥120 ms. There were differences in LVEDD and severity of MR on echocardiography, but no difference between the groups with regard to LVEF, drug profiles and the Swan-Ganz hemodynamic data. Event-free survival as evaluated by Kaplan-Meier analysis was significantly lower in the prolonged-QRS group than in the narrow-QRS group (Fig 1) . MR We also divided the patient population on the basis of the severity of MR (Table 5) : 52 patients (63.5%) had no or mild MR and the other 26 patients had moderate or severe MR. Between the 2 groups, there were differences in age and cardiac index. More patients in the severe MR group were NYHA class III or IV. There was no difference in LVEF, LVEDD or LAd between these 2 groups. Eventfree survival as evaluated by Kaplan-Meier analysis was significantly lower in the severe MR group than in the mild MR group (Fig 2) .
Echocardiographic Follow-up
Echocardiographic studies were performed during follow-up after the introduction of an ACEI/ARB and/orblocker. In 40 patients (66.7%), the LVEDD was reduced from the value measured at the time of diagnosis of Fig 5 . Correlation between the change of the severity of MR and the percent change in Dd. The percentage change in Dd was defined as: (Dd measured during follow-up after optimal medical therapy -Dd measured at the first diagnosis of NIDCM)/Dd measured at the first diagnosis of NIDCM. The change of the severity of MR was negatively correlated with the percent change in Dd (R=-0.311; p=0.0204). MR, mitral regurgitation; NIDCM, nonischemic dilated cardiomyopathy. Fig 2. Kaplan-Meier event-free curves for nonischemic dilated cardiomyopathy patients stratified into 2 groups according to the severity of mitral regurgitation. Cardiac death and hospitalization due to the deterioration of heart failure were defined as negative events. MR, mitral regurgitation. NIDCM, which meant reverse remodeling of the LV after optimal medical therapy. The percentage change in LVEDD was highly correlated with QRS duration (R=0.577, p< 0.0001) (Fig 3) . Thus, QRS duration at the first diagnosis of NIDCM seemed to predict reverse remodeling after optimal medical therapy. Other parameters, such as LVEF and LVEDD, were not correlated with the percentage change in LVEDD. The severity of MR was also examined at the first diagnosis of NIDCM and at follow-up. In 8 patients the severity of MR had increased, had improved in 10 patients and was unchanged in the remaing patients. The correlation value between the change in the severity of MR and QRS duration was -0.279 (p=0.0427) (Fig 4) . The correlation value between the change in the severity of MR and the LVEDD percent change was -0.311 (p=0.0204) (Fig 5) .
Discussion
The introduction of -blockers and ACEI/ARBs significantly improved the survival of patients with either ischemic cardiomyopathy or NIDCM. [4] [5] [6] [7] [8] [9] Konstam et al reported that ACEI and -blockers can slow or reverse LV dilation and remodeling in patients with heart failure and the main effects of ACEI on LV dilation are observed in the first few months of therapy. 10 However, even after the introduction of these medications, there are still some cases that are difficult to manage medically and for these biventricular pacemaker therapy or surgical intervention, such as heart transplantation or the Batista procedure, are indicated. Therefore, risk prediction in patients with NIDCM is crucial for selection of the best treatment strategy. Before the advent of anti-remodeling medications, Gravazzi et al reported that PCWP and the LAd index were significant predictors of prognosis in NIDCM patients. 11 But since then there have been few reports about the predictive factors of heart failure in NIDCM patients after administration of these medications.
Our principal findings are that QRS duration, severity of MR and LVEF predict cardiac death and deterioration of heart failure in NIDCM patients treated with ACEI/ARBs and/or -blockers
QRS Duration
A prolonged QRS duration was recently reported as an unfavorable prognostic factor in heart disease and others have suggested that a prolonged QRS duration is an independent or contributing risk factor for mortality in patients with heart failure. 12 However, in contrast to the present study, those studies included many patients with ischemic heart disease, whereas we focused on the association between patients with NIDCM and QRS duration. Our results are concordant with those from recent trials highlighting the potential mortality impact of QRS duration in patients with heart disease.
There are several reports about correlation between QRS duration and other clinical variables. Rachel reported that a prolonged QRS duration on the surface ECG is a specific indicator of LV dysfunction, 13 and Sandhu and Bahler also reported that 25% of community hospital patients with heart failure requiring hospitalization had a QRS duration >120 ms and that this degree of QRS prolongation was associated with more severe LV systolic dysfunction, dilation, and MR. 14 However, in the present study, the association between LVEF and QRS duration was not clearly evident because the patient population was restricted to those with impaired LV function. Yamada et al reported that progressive myocardial fibrosis leads to dyssynchronous activation of the left and right ventricles and a prolonged QRS duration. 15 Possible clinical consequences of ventricular asynchrony, which presents as prolonged QRS duration on ECG, include abnormal interventricular septal wall motion, a reduction in the peak rate of rise of LV pressure, reduced diastolic filling times, and prolonged duration of MR. These factors all appear to be associated with an unfavorable prognosis in heart failure.
MR
In patients with end-stage cardiomyopathy, MR clearly has a negative impact on survival. Volume overload secondary to MR further increases ventricular dilation and the subsequent annular dilatation further increases the degree of MR, resulting in a vicious cycle that leads to severe MR in the presence of severe LV dysfunction. In this study, MR was an independent prognostic predictor of cardiac death or deterioration of heart failure in NIDCM. Functional MR is a marker for high mortality among patents with cardiomyopathy. 16 Recently, Todd et al reported that severe MR represents a high-risk subset of patients with LV systolic dysfunction. For the treatment of MR, mitral valve reconstruction for the correction of secondary MR in patients with end-stage DCM and refractory congestive heart failure has an acceptable 1-year mortality and improves symptoms and LV shape and performance. 17, 18 Rossi et al reported that MR volume was a key determinant of left atrial (LA) volume, 19 but in our study there was no significant difference in LAd between the mild and severe MR groups. In our opinion, LA volume appeared to be associated with LV remodeling, diastolic dysfunction and concomitant atrial myopathic disease rather than with severity of MR in NIDCM patients, 20 and in fact LAd was moderately correlated with LVEDD (R=0.453 p=0.0036).
AF
AF was detected in 26 of the 74 patients (35.1%), a percentage similar to a previous Japanese report. 21 In this study, it was not a predictor of cardiac death or deterioration of heart failure, although an association between heart failure and AF has been frequently reported. However, in DCM in which systolic function is severely impaired, the negative hemodynamic effect of AF may be masked by the severe systolic dysfunction.
Echocardiographic Follow-up Data
We found that the percentage change in LVEDD was inversely correlated with QRS duration recorded at the first diagnosis of NIDCM. The percentage change in LVEDD indicated reverse remodeling of the LV. Therefore, QRS duration at the first diagnosis of NIDCM was a predictor of reverse remodeling after anti-remodeling therapy. The QRS duration appeared to reflect the extent of fibrosis in the LV and a narrow QRS duration indicated less fibrosis and the potential for a greater reduction in LV diameter. This make a contrast with the case with biventricular pacing therapy, which results in LV reverse remodeling in heart failure patients with a wide QRS complex. Cheuk-Man examined potential predictors of reverse remodeling with biventricular pacemaker therapy and systolic dyssynchrony was the only independent predictor. Alonso et al reported that clinical responders had a reduced QRS duration after biventricular pacing. 22 Circulation Journal Vol.70, January 2006 QRS duration was also slightly associated with the change in the severity of MR in our study. Patients with narrow QRS duration were more likely to show an improvement in the severity of MR during follow up. It is expected that interventions that can reduce QRS duration would also improve the severity of MR; however, there is insufficient evidence for the effectiveness of resynchronization therapy for MR. 23 MR was an independent predictor of heart failure and should be treated after narrowing the QRS duration by resynchronization therapy.
Study Limitation
The total number of patients available for analysis was small, but nevertheless, statistically meaningful outcome data were obtained.
Conclusion
The severity of MR and QRS duration were the strongest predictors of cardiac events in cases of NIDCM. In the treatment of NIDCM, patients who have a prolonged QRS duration or severe MR might benefit from aggressive therapy such as biventricular pacing and surgical intervention to correct the MR in the early stages of the disease. In addition, QRS duration appears to represent the most powerful predictor of remodeling and therefore is very useful marker in clinical decision making.
